UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported)
November 9, 2017

 

ALLIED HEALTHCARE PRODUCTS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware  0-19266  25-1370721 
(State or Other Jurisdiction
of Incorporation)		 (Commission
File Number)		 (IRS Employer
Identification No.)

 

1720 Sublette Avenue, St. Louis, Missouri 
(Address of principal executive offices)		 63110
(Zip Code)

 

Registrant’s telephone number, including area code 
(314) 771-2400 
 
Not applicable 
(Former name or former address, if changed since last report) 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

ITEM 5.07.    Submission of Matters to a Vote of Security Holders.

 

The annual meeting of the stockholders of Allied Healthcare Products, Inc. (the “Company”) was held on November 9, 2017. Proxies were solicited pursuant to Regulation 14A of the Securities Exchange Act of 1934. There was no solicitation in opposition to management’s nominees for Directors. The voting results are noted below.

 

ELECTION OF DIRECTORS

 

All nominees for Directors were elected with the following votes cast:

 

  For   Withheld   Broker Non-Votes
Judith T. Graves 2,213,834   22,506   1,252,284
Joseph E. Root 2,213,785   22,556   1,252,284
William A. Peck 2,209,766   26,574   1,252,284
Earl R. Refsland 2,214,739   21,426   1,252,284
John D. Weil 2,199,698   35,458   1,252,284

 

Agenda Item 2, concerning the ratification of the appointment of RubinBrown LLP as the Company’s independent registered public accounting firm for fiscal 2018 was approved by the stockholders with the following votes cast:

 

For   Against   Abstain   Broker Non-Votes
3,423,657   54,520   10,471   0

 

Agenda Item 3, an advisory (non-binding) vote to approve our executive compensation was approved by the stockholders with the following votes cast:

 

For   Against   Abstain   Broker Non-Votes
2,174,992   28,011   33,361   1,252,284

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  ALLIED HEALTHCARE PRODUCTS, INC.
   
   
Date: November 13, 2017 By:  /s/ Daniel C. Dunn
    Daniel C. Dunn
Chief Financial Officer